Navigation Links
Rik Deitsch, CEO of Nutra Pharma Creates Personal Wall on WallSt.net's Financial Social Community, my.wallst.net
Date:4/18/2008

NEW YORK, April 18 /PRNewswire-FirstCall/ -- Rik J. Deitsch, Chairman and Chief Executive Officer of Nutra Pharma Corporation (OTC Bulletin Board: NPHC) (http://www.NutraPharma.com) will be updating the investment community through his personal profile on MyWallst.net available at http://www.wallst.net. The dynamic profile will include exclusive interviews with Rik J. Deitsch, company blogs on which investors can comment, his personal stock watchlist, photos of company products and links to recent press.

Visit Rik J. Deitsch's profile on My.wallst.net at http://my.wallst.net/profile.php?ID=20002.

Stay updated about Nutra Pharma Corporation, ask Rik a question or post a comment on his personal page. Join Nutra Pharma's message board to discuss company activity with other interested parties, "invest" in OTCBB: NPHC through the Rookie Challenge and join his financial social network today.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://my.wallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of compliance solutions to publicly traded companies. We have received ten thousand dollars from Nutra Pharma Corporation for media and advertising services. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site.

About Nutra Pharma:

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ('MS'). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Contact: Nutra Pharma Corporation

877-895-5647

IR@NutraPharma.com


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
2. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
3. NutraCea Appoints New Chief Financial Officer
4. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
5. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
6. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
7. Nutraceutical Reports Fiscal 2008 Q1 Results
8. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
9. NutraCea Files Universal Shelf Registration Statement
10. NutraCea Provides Update on Domestic Operations
11. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often ... it difficult for lab operators and management to assess these processes with a ... wasteful or unnecessary actions. , Created with the help of both internal ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, and Omega ... Omega Station” is the creation of published author, Chris Jackson. Chris Jackson grew ... works in the Dallas Independent School District teaching English. He is heavily involved in ...
(Date:4/24/2017)... ... ... A 2-in-1 bottleless water appliance provides both purified drinking ... here are the ways in which this technology can benefit dental offices: , ... oxygenated water, with both cold and hot options. , Convenience for Dentists and ...
(Date:4/22/2017)... (PRWEB) , ... April 22, 2017 , ... ... shows that U.S. consumers can save an average of 70% when buying medication ... (up to 97%) are available when purchasing from other countries. The report (chart ...
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  New research provides evidence that an old ... to a study released today that will be presented at ... in Boston , April 22 to 28, ... of Parkinson,s disease, the oral drug levodopa has long been ... But as the disease progresses, the effects of the medication ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: